Literature DB >> 20306296

Predictive models for nucleoside bisubstrate analogs as inhibitors of siderophore biosynthesis in Mycobacterium tuberculosis: pharmacophore mapping and chemometric QSAR study.

Nilesh R Tawari1, Mariam S Degani.   

Abstract

Inhibitors of aryl acid adenylating enzymes (AAAE), known as MbtA, involved in siderophore biosynthesis in Mycobacterium tuberculosis, are being explored as potential antitubercular agents. In this article, we report the development of a robust pharmacophore model and investigation of structure-activity relationship of several nucleoside bisubstrate analogs reported as MbtA inhibitors. The developed pharmacophore model revealed the importance of two hydrogen bond donors and one hydrogen bond acceptor features. Furthermore, it was found that an aromatic ring at the distal part of molecule away from the two aromatic rings of adenyl moiety is a critical requirement for the tight binding of inhibitor. The generated pharmacophore-based alignment was used to derive a predictive atom-based 3D-QSAR model for training set (r (2) = 0.97, SD = 0.23, F = 310.6, N = 48) and test set (Q (2) = 0.71, RMSE = 0.65, Pearson-R = 0.85, N = 15). Structure-activity relationship investigation further revealed that bulky substitutions at the C-6 position of adenyl moiety is detrimental to activity, while hydrophobic substitutions can be tolerated at C-2 position. Taken together, the PLS-generated QSAR regression cubes along with developed pharmacophore model provide a qualitative picture of the active site and can be used as a powerful tool for the rational modification of bisubstrate inhibitors of MbtA in search of better antitubercular agents. Furthermore, a three-class classification chemometric QSAR model was developed using molecular descriptors for the prediction of whole-cell activity which could be used in the predictive layer for screening of compounds before synthesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20306296     DOI: 10.1007/s11030-010-9243-8

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  24 in total

1.  Prediction of drug solubility from Monte Carlo simulations.

Authors:  W L Jorgensen; E M Duffy
Journal:  Bioorg Med Chem Lett       Date:  2000-06-05       Impact factor: 2.823

2.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

3.  Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis.

Authors:  Ravindranadh V Somu; Helena Boshoff; Chunhua Qiao; Eric M Bennett; Clifton E Barry; Courtney C Aldrich
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

4.  Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: antibacterial nucleosides effective against Mycobacterium tuberculosis.

Authors:  Amol Gupte; Helena I Boshoff; Daniel J Wilson; João Neres; Nicholas P Labello; Ravindranadh V Somu; Chengguo Xing; Clifton E Barry; Courtney C Aldrich
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

Review 5.  Aminoacyl tRNA synthetases as targets for new anti-infectives.

Authors:  P Schimmel; J Tao; J Hill
Journal:  FASEB J       Date:  1998-12       Impact factor: 5.191

6.  Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin.

Authors:  L E Quadri; J Sello; T A Keating; P H Weinreb; C T Walsh
Journal:  Chem Biol       Date:  1998-11

Review 7.  The envelope of mycobacteria.

Authors:  P J Brennan; H Nikaido
Journal:  Annu Rev Biochem       Date:  1995       Impact factor: 23.643

8.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

9.  Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains.

Authors:  R D Fleischmann; D Alland; J A Eisen; L Carpenter; O White; J Peterson; R DeBoy; R Dodson; M Gwinn; D Haft; E Hickey; J F Kolonay; W C Nelson; L A Umayam; M Ermolaeva; S L Salzberg; A Delcher; T Utterback; J Weidman; H Khouri; J Gill; A Mikula; W Bishai; W R Jacobs; J C Venter; C M Fraser
Journal:  J Bacteriol       Date:  2002-10       Impact factor: 3.490

Review 10.  Enterobactin: an archetype for microbial iron transport.

Authors:  Kenneth N Raymond; Emily A Dertz; Sanggoo S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

View more
  1 in total

Review 1.  In Silico Strategies in Tuberculosis Drug Discovery.

Authors:  Stephani Joy Y Macalino; Junie B Billones; Voltaire G Organo; Maria Constancia O Carrillo
Journal:  Molecules       Date:  2020-02-04       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.